Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Post-Transplant Cyclophosphamide, Abatacept and Short Course of Tacrolimus (CAST) for Graft-Versus-Host Disease Prevention Following Haploidentical Peripheral Blood Stem Cell Transplantation

A Samer Al-Homsi, Frank Cirrone, Kelli Cole, Jaime Andres Suarez-Londono, Sharon L. Gardner, Jingmei Hsu, Stephanie Wo, Kelsey Stocker, Benedetto Bruno, Judith Goldberg, Benjamin Levinson, Maher Abdul-Hay

Blood (2022) 140 (Supplement 1): 7628–7630.

https://doi.org/10.1182/blood-2022-162634

Published: 2022

Journal Articles

Post-Transplant High Dose Cyclophosphamide and Bortezomib As Graft-Versus-Host Disease Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation

Benedetto Bruno, Frank Cirrone, Kelli Cole, Kelsey Stocker, Maher Abdul-Hay, J Andres Suarez-Londono, Tsivia Hochman, Judith Goldberg, A Samer Samer Al-Homsi

Blood (2021) 138 (Supplement 1): 3892.

https://doi.org/10.1182/blood-2021-151809

Published: 2021

Journal Articles

Post-Transplant Cyclophosphamide, Abatacept, and Short Course of Tacrolimus Combination (CAST) Is Safe and Seems Highly Effective in Preventing Graft-Versus-Host Disease Following Haploidentical Peripheral Blood Stem Cell Transplantation

A Samer Samer Al-Homsi, Frank Cirrone, Kelli Cole, Kelsey Stocker, Benedetto Bruno, J Andres Suarez-Londono, Judith Goldberg, Maher Abdul-Hay

Blood (2021) 138 (Supplement 1): 3906.

https://doi.org/10.1182/blood-2021-150856

Published: 2021

Journal Articles

Post-Transplant Cyclophosphamide Overcomes Graft-Versus-Host Disease Aggravation Induced By Extended Administration of Proteasome Inhibitors

A. Samer Al-Homsi, MD, Austin Goodyke, Kelli Cole, MSN, Marlee Muilenburg, BSN, Michael McLane, Sarah Abdel-Mageed, Muneer H. Abidi, MD, Stephanie F. Williams, MD

Blood (2016) 128 (22): 4543.

https://doi.org/10.1182/blood.V128.22.4543.4543

Published: 2016

Journal Articles

Bendamustine, Carfilzomib, and Melphalan (BCM) Conditioning Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Feasibility Study

A. Samer Al-Homsi, MD, Marlee Muilenburg, BSN, Kelli Cole, MSN, Muneer H. Abidi, MD, Stephanie F. Williams, MD

Blood (2016) 128 (22): 4635.

https://doi.org/10.1182/blood.V128.22.4635.4635

Published: 2016

Journal Articles

Ixazomib Impairs Dendritic Cell Function and T Cell Proliferation and Affects the Development of GvHD in a Schedule-Dependent Fashion

Yuxin Feng, PhD, Austin Goodyke, Marlee Muilenberg, BSN, RN, Kelli Cole, MSN, RN, Kathleen Cannady, DVM, Anding Shen, PhD, A. Samer Al-Homsi, MD

Blood (2015) 126 (23): 1881.

https://doi.org/10.1182/blood.V126.23.1881.1881

Published: 2015

Journal Articles

Post-Transplant Cyclophosphamide and Bortezomib Combination for Prevention of GvHD after Allogeneic Blood and Marrow Transplantation Is Feasible and Produces Favorable Outcomes

A. Samer Al-Homsi, MD, Tara S Roy, NP, Kelli Cole, RN, MSN, Marlee Bogema, RN, BSN, Stephanie F Williams, MD, Ulrich A. Duffner, MD, Aly Mageed, MD

Blood (2014) 124 (21): 3920.

https://doi.org/10.1182/blood.V124.21.3920.3920

Published: 2014

NARROW

Post-Transplant Cyclophosphamide, Abatacept and Short Course of Tacrolimus (CAST) for Graft-Versus-Host Disease Prevention Following Haploidentical Peripheral Blood Stem Cell Transplantation

Post-Transplant High Dose Cyclophosphamide and Bortezomib As Graft-Versus-Host Disease Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation

Post-Transplant Cyclophosphamide, Abatacept, and Short Course of Tacrolimus Combination (CAST) Is Safe and Seems Highly Effective in Preventing Graft-Versus-Host Disease Following Haploidentical Peripheral Blood Stem Cell Transplantation

Post-Transplant Cyclophosphamide Overcomes Graft-Versus-Host Disease Aggravation Induced By Extended Administration of Proteasome Inhibitors

Bendamustine, Carfilzomib, and Melphalan (BCM) Conditioning Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Feasibility Study

Ixazomib Impairs Dendritic Cell Function and T Cell Proliferation and Affects the Development of GvHD in a Schedule-Dependent Fashion

Post-Transplant Cyclophosphamide and Bortezomib Combination for Prevention of GvHD after Allogeneic Blood and Marrow Transplantation Is Feasible and Produces Favorable Outcomes

Email alerts

ASH Publications

American Society of Hematology

Post-Transplant Cyclophosphamide, Abatacept and Short Course of Tacrolimus (CAST) for Graft-Versus-Host Disease Prevention Following Haploidentical Peripheral Blood Stem Cell Transplantation

Post-Transplant High Dose Cyclophosphamide and Bortezomib As Graft-Versus-Host Disease Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation

Post-Transplant Cyclophosphamide, Abatacept, and Short Course of Tacrolimus Combination (CAST) Is Safe and Seems Highly Effective in Preventing Graft-Versus-Host Disease Following Haploidentical Peripheral Blood Stem Cell Transplantation

Post-Transplant Cyclophosphamide Overcomes Graft-Versus-Host Disease Aggravation Induced By Extended Administration of Proteasome Inhibitors

Bendamustine, Carfilzomib, and Melphalan (BCM) Conditioning Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Feasibility Study

Ixazomib Impairs Dendritic Cell Function and T Cell Proliferation and Affects the Development of GvHD in a Schedule-Dependent Fashion

Post-Transplant Cyclophosphamide and Bortezomib Combination for Prevention of GvHD after Allogeneic Blood and Marrow Transplantation Is Feasible and Produces Favorable Outcomes

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only